PF4 and glioblastoma: Serum biomarkers, S100A8, S100A9, and CXCL4, were identified from GBM patients' serum by using surface‐enhanced laser desorption/ionization time‐of‐flight and liquid chromatography–MS/MS technologies (Popescu et al., 2014).